4.1 Review

Neuroimaging in Dementia

Journal

SEMINARS IN NEUROLOGY
Volume 28, Issue 4, Pages 467-483

Publisher

THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0028-1083695

Keywords

MRI; PET; Pittsburgh Compound-B; dementia; neurodegenerative disease

Funding

  1. NIA [K23AG021989]
  2. NIH-NIA [1P01 AG021601]
  3. Fondazione Tronchetti-Provera, Milan, Italy
  4. NATIONAL INSTITUTE ON AGING [K23AG021989, P01AG021601] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Although dementia is a clinical diagnosis, neuroimaging often is crucial for proper assessment. Magnetic resonance imaging (MRI) and computed tomography (CT) may identify nondegenerative and potentially treatable causes of dementia. Recent neuroimaging advances, such as the Pittsburgh Compound-B (PIB) ligand for positron emission tomography imaging in Alzheimer's disease, will improve our ability to differentiate among the neurodegenerative dementias. High-resolution volumetric MRI has increased the capacity to identify the various forms of the frontotemporal lobar degeneration spectrum and some forms of parkinsonism or cerebellar neurodegenerative disorders, such as corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, and spinocerebellar ataxias. In many cases, the specific pattern of cortical and subcortical abnormalities on MRI has diagnostic utility. Finally, among the new MRI methods, diffusion-weighted MRI can help in the early diagnosis of Creutzfeldt-Jakob disease. Although only clinical assessment can lead to a diagnosis of dementia, neuroimaging is clearly an invaluable tool for the clinician in the differential diagnosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available